ESR1 and breast cancer: Combining these with drugs targeting other key factors of cancer cells, in particular other molecular ERα partners in BC, represents a rationale way to try to improve their therapeutic efficacy, allowing, for example, to lower their effective dosage thereby reducing side effects.